SNX-2112 100mg

SNX-2112 is a heat shock protein 90 (Hsp90) inhibitor with anticancer properties currently in clinical trials. SNX-2112 induced autophagy in a time- and dose-dependent manner via Akt/mTOR/p70S6K inhibition. SNX-2112 induces significant apoptosis and autophagy in human melanoma A-375 cells, and may be an effective targeted therapy agent

Price Not Available 100mg SNX-2112 100mg Supplier Page

Trivial name	SNX-2112 100mg
Catalog Number	A11189-100
Alternative Name(s)	2-[(trans-4-Hydroxycyclohexyl)amino]-4-[4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1H-indazol-1-yl]benzamide
Molecular Formula	C23H27F3N4O3
CAS#	908112-43-6
SMILES	CC1(CC2=C(C(=O)C1)C(=NN2C3=CC(=C(C=C3)C(=O)N)NC4CCC(CC4)O)C(F)(F)F)C
Size	100mg
Supplier Page	http://www.adooq.com/snx-2112.html